## Abstract In stage IV nonβHodgkin's lymphomas, CVP (cyclophosphamide, vincristine, and prednisone) was randomly compared to ABP (adriamycin, bleomycin, and prednisone). Of 62 patients entered into the study, 57 (CVP 27, ABP 30) were considered evaluable for comparison. In patients with liver and/
Staging and treatment with cyclophosphamide, vincristine and prednisone (CVP) in advanced cutaneous t-cell lymphomas
β Scribed by Umberto Tirelli; Antonino Carbone; Vittorina Zagonel; Rachele Volpe; Andrea Veronesi; Enzo Galligioni; Salvatore Tumolo; Fulvio Brema; Mauro G. Trovo; Eligio Grigoletto
- Publisher
- John Wiley and Sons
- Year
- 1986
- Tongue
- English
- Weight
- 529 KB
- Volume
- 4
- Category
- Article
- ISSN
- 0278-0232
No coin nor oath required. For personal study only.
β¦ Synopsis
Twenty-three consecutive patients with cutaneous T-cell lymphomas were submitted to staging procedures including lymphangiography, bone marrow biopsy and aspiration, peripheral blood morphological examination, peritoneoscopy with liver and spleen biopsy, and in selected patients lymph node biopsies. Extracutaneous disease (lymph nodes, bone marrow, liver and spleen) was detected in 12 patients. Bone marrow was involved in 25 per cent of the patients at presentation (all patients had lymph node involvement) and in two of nine patients with advanced disease during the follow-up. Peripheral blood was involved in 65 per cent of the patients at presentation (ten patients with advanced disease) and in six of nine patients with advanced disease during the follow-up. In 16 patients with advanced disease (T3-T4 and/or extracutaneous disease), CVP was given with a 50 per cent objective response rate and four complete remissions of 47+, 12+, 19 and 19 months duration. Median survival of patients with advanced disease was 4 years.
π SIMILAR VOLUMES
This Phase II study was undertaken to assess the efficacy and toxicity of chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone (EPOCH regimen) in patients with advanced, refractory cutaneous T-cell lymphoma (CTCL). ## METHODS. Fifteen patients were tre
Ninety-six patients with advanced chronic lymphocytic leukemia (CLL) (Stage C; anemia and/or thrombocytopenia of nonimmune origin) were randomized to receive either chlorambucil (CLR) (0.4 mg/kg orally, day 6) plus prednime (PDN) (60 mg/m2 orally, days 1-5) every 2 weeks or cyclophosphamide (600 mg/